Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iterum Therapeutics plc    ITRM   IE00BF3W0Q35

ITERUM THERAPEUTICS PLC

(ITRM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
0.7626(c) 0.7318(c) 0.66(c) 0.65(c) 0.841 Last
1 982 560 5 102 012 3 622 758 7 569 316 99 592 036 Volume
-4.28% -4.04% -9.81% -1.52% +29.38% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -44,0 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,35x
Yield 2020 -
Sales 2021 3,20 M - -
Net income 2021 -39,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,30x
Yield 2021 -
Capitalization 36,2 M 36,2 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 11,3x
Nbr of Employees 44
Free-Float 98,7%
More Financials
Company
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a... 
More about the company
Notations Surperformance© of Iterum Therapeutics plc
Trading Rating : Investor Rating : -
More Ratings
All news about ITERUM THERAPEUTICS PLC
11/30Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Admini..
GL
11/16ITERUM THERAPEUTICS : Xbrl q3 2020
PU
11/16Iterum Therapeutics Reports Third Quarter 2020 Financial Results
GL
10/23Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offerin..
GL
10/19UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncompli..
GL
10/19Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and ..
GL
09/30Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem..
GL
09/08Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Inve..
GL
09/02Iterum Therapeutics Announces Revised Results of Rights Offering
GL
08/31Iterum Therapeutics Announces Expiration and Preliminary Results of Rights Of..
GL
08/11Iterum Therapeutics Commences Rights Offering
GL
08/06Iterum Therapeutics Reports Second Quarter 2020 Financial Results
GL
07/13Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Of..
GL
06/29Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial..
GL
06/15Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meet..
GL
More news
News in other languages on ITERUM THERAPEUTICS PLC

- No features available -

More news
Chart ITERUM THERAPEUTICS PLC
Duration : Period :
Iterum Therapeutics plc Technical Analysis Chart | ITRM | IE00BF3W0Q35 | MarketScreener
Technical analysis trends ITERUM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 1,75 $
Last Close Price 0,84 $
Spread / Highest target 138%
Spread / Average Target 108%
Spread / Lowest Target 78,4%
EPS Revisions
Managers
NameTitle
Corey N. Fishman President, Chief Executive Officer & Director
Brent K. Ahrens Chairman
Benjamin M. Pe Vice President-Operations
Judith M. Matthews Chief Financial Officer
Michael W. Dunne Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ITERUM THERAPEUTICS PLC-85.56%28
MODERNA, INC.631.08%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.93.92%42 101
IQVIA HOLDINGS INC.10.05%32 601
SEAGEN INC.54.94%31 921